China’s Xian Giant Biogene Technology has embarked on a fundraising round that will likely see Hillhouse Capital Group and others buy at least 4 billion yuan ($630 million) worth of shares, two people familiar with the matter said.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com